Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C.

被引：0
|
作者：
Jensen, CDM
Bernstein, DE
Hassanein, TI
Foster, GR
Lee, SS
Cheinquer, H
Craxi, A
Cooksley, WGE
Klaskala, W
Green, J
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] N Shore Univ Hosp, Manhasset, NY USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ London Imperial Coll Sci Technol & Med, London, England
[5] Univ Calgary, Calgary, AB, Canada
[6] Univ Fed Rio Grande Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[7] Inst Clin Med Policlin, Palermo, Italy
[8] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia
[9] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1761
引用
收藏
页码：603A / 603A
页数：1
相关论文
共 50 条
  • [1] Effect of ethnicity on the pharmacokinetics of ribavirin (COPEGUS®) and peginterferon alfa-2a (40kd) (PEGASYS®) in patients with chronic hepatitis C
    Brennan, B
    Morrison, R
    Hagedorn, C
    Marbury, TC
    Sulkowski, M
    Grippo, J
    Gries, JM
    HEPATOLOGY, 2005, 42 (04) : 652A - 653A
  • [2] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [3] Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    Sherman, M.
    Yoshida, E. M.
    Deschenes, M.
    Krajden, M.
    Bain, V. G.
    Peltekian, K.
    Anderson, F.
    Kaita, K.
    Simonyi, S.
    Balshaw, R.
    Lee, S. S.
    GUT, 2006, 55 (11) : 1631 - 1638
  • [4] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [5] A dynamic model to predict sustained virological response to combination peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) therapy in patients with chronic hepatitis C.
    Ferenci, P
    Fried, MW
    Chaneac, M
    HEPATOLOGY, 2003, 38 (04) : 635A - 635A
  • [6] Peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin in chronic hepatitis C:: Retreatment of patients who relapsed virologically after 24 weeks of therapy.
    Goncales, F
    Bernstein, DE
    Berg, C
    Sette, H
    Rasenack, J
    Diago, M
    Jensen, DM
    Cooksley, WGE
    Roberts, P
    Ackrill, AM
    HEPATOLOGY, 2002, 36 (04) : 361A - 361A
  • [7] The cost-effectiveness of peginterferon alfa-2a (40kd) (PEGASYS) plus ribavirin (COPEGUS) vs. interferon alfa-2b plus ribavirin for chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Craxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    VALUE IN HEALTH, 2003, 6 (03) : 262 - 263
  • [8] An evaluation of the cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for the first treatment of mild chronic hepatitis C (CHC)
    Hornberger, J
    Dusheiko, G
    Lewis, G
    Patel, K
    HEPATOLOGY, 2005, 42 (04) : 653A - 653A
  • [9] Combination of Levovirin (LVV) and peginterferon alfa-2a (40 KD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40KD) in patients with chronic hepatitis
    Pockros, PJ
    Pessoa, MG
    Diago, M
    Martinelli, ADC
    Berg, T
    Germanidis, G
    Lai, MY
    Gomez, HR
    Goeser, T
    Roberts, S
    Sheen, IS
    Hsien, T
    Hinrichsen, HM
    Lee, SS
    Reindollar, R
    Sola, R
    Wilson, K
    Jorga, K
    Graham, P
    Jackson, H
    HEPATOLOGY, 2004, 40 (04) : 391A - 391A
  • [10] A comparison of cost effectiveness of peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Crtaxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    JOURNAL OF HEPATOLOGY, 2003, 38 : 174 - 175
12345